Background: Atrophic rhinitis is a chronic debilitating nasal disease which may be primary, or secondary to various underlying etiologies. Several methods of treatment have been previously adopted with minimal success rate. In order to achieve effective and long-standing method of treatment for this challenging pathology, this method should work mainly on reversal of the pathologic changes in nasal microanatomy. Objective: Review article investigating the use of platelet- rich plasma in treatment of atrophic rhinitis. Methods: We scoured scholarly journals and databases including PubMed, Google Scholar, and Science Direct for reports on Treatment of atrophic rhinitis, Platelet-rich plasma and new biological modality between November 1990 and April 2023. However, only the latest or most comprehensive study was considered. The authors also assessed the usefulness of references drawn from similar books. As a result, non-English documents have been overlooked due to a lack of resources to translate them. It was commonly recognized that scientific research did not include things like unpublished publications, oral presentations, conference abstracts, or dissertations. Conclusion: Platelet Rich Plasma (PRP) is a plasma fraction with a very high platelet content that also contains phagocytic cells, a significant amount of fibrinogen, a number of chemotactic factors and cytokines that may be used to control tissue inflammatory response, as well as growth factors that can help with tissue healing and regeneration. It is now considered the best treatment for treating atrophic rhinitis as a result.